NOVA SCOTIA

FIRAZYR is covered by Nova Scotia Pharmacare (Exception Drug Status Program)

Eligibility

For FIRAZYR to be eligible for coverage by Nova Scotia Pharmacare, prescribers must submit an Exception Status Drug request and the request must be approved before the patient fills the prescription. Deductibles may apply. For more information concerning the reimbursement process, contact OnePath®.

Reimbursement Criteria

We are pleased to inform you that FIRAZYR (icatibant acetate) is reimbursed in Nova Scotia for your hereditary angioedema (HAE) patients who meet the following criteria:

For the treatment of acute attacks of HAE in adults with lab confirmed C1-esterase inhibitor deficiency (type I or type II) under the following conditions:

  • Treatment of non-laryngeal attacks of at least moderate severity, OR
  • Treatment of acute laryngeal attack

Notes:

  • Limited to a single dose for self-administration per attack
  • Must be prescribed by physicians with experience in the treatment of HAE

Claim Notes:

  • Maximum of two doses on hand at any time

OnePath® Patient Support Program will help navigate insurance coverage and access reimbursement to medication through private and public insurance companies.

Find Out More

Source: Nova Scotia Formulary. March 2022.
https://novascotia.ca/dhw/pharmacare/documents/formulary.pdf